Clinical Trial: Does Radioiodine Treatment Prevent Atrial Fibrillation and Bone Loss in Endogenous Subclinical Hyperthyroidism?

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Subclinical Hyperthyroidism ”To Treat or Not to Treat?” A Dutch Multicenter Trial

Brief Summary: Subclinical hyperthyroidism is defined as the presence of serum free thyroxine (T4) and triiodothyronine (T3) levels within the reference range and a reduced serum thyrotrophin (TSH) level. Evidence is accumulating that it has important clinical effects. The SUBstudy is a randomised, Dutch multicenter trial to study whether radioiodine treatment prevents the development of atrial fibrillation and prevents decreases in bone mineral density in patients with endogenous subclinical hyperthyroidism.

Detailed Summary:
Sponsor: Radboud University

Current Primary Outcome: To provide evidence that restoration of euthyroidism (normal TSH) improves thyrotoxic symptoms and signs and quality of life and lowers the risk of subsequent atrial fibrillation and bone loss in subjects with endogenous subclinical hyperthyroidism

Original Primary Outcome: To provide evidence that restoration of euthyroidism (normal TSH) improves thyrotoxic symptoms and signs and quality of life and lowers the risk of subsequent atrial fibrillation and bone loss in subjects with endogenous subclinical hyperthyroidism.

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Radboud University

Dates:
Date Received: September 8, 2005
Date Started: April 2004
Date Completion:
Last Updated: July 17, 2007
Last Verified: September 2005